Literature DB >> 9352606

Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis.

M Field1, A Cook, G Gallagher.   

Abstract

Temporal arteritis (TA) is an acute vasculitis characterised by destruction of arterial architecture following infiltration of the arterial wall by macrophages, giant cells and lymphocytes. Using immunohistochemical techniques, tumour necrosis factor (TNF) was demonstrated in up to 60% of the cells in all areas of inflamed arteries. More cells staining for TNF were detected in the intima and media of inflamed vessels than control uninflamed arteries (P < 0.003 and P < 0.001, respectively). In TA, TNF was localised to giant cells and macrophages, suggesting that its predominant source is from the monocyte lineage, but, occasionally, TNF staining was found in areas infiltrated by T cells. Many endothelial cells also contained TNF, but there were no differences between the number of endothelial cells staining in inflamed and normal blood vessels. Of the two TNF receptors, the p75 receptor was sparsely represented in the inflamed vessels in TA. By comparison, the p55 receptor was widely detected on endothelial cells and infiltrating mononuclear cells close to the internal elastic lamina (IEL). Endothelial cells from normal vessels also stained for both TNF receptors, but normal smooth muscle cells in the vessel media expressed the p55 receptor, indicating that they are capable of responding to locally secreted TNF. Localisation of TNF receptors and TNF in close proximity to the IEL suggests that TNF could be involved in the leucocyte infiltration and arterial wall destruction characteristic of TA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352606     DOI: 10.1007/s002960050019

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

Review 1.  New indications for biological therapies.

Authors:  Mariagrazia Catanoso; Nicolò Pipitone; Luca Magnani; Luigi Boiardi; Carlo Salvarani
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Treatment of refractory temporal arteritis with adalimumab.

Authors:  M Mubashir Ahmed; Eisha Mubashir; Samina Hayat; Marjorie Fowler; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

3.  Infliximab as monotherapy in giant cell arteritis.

Authors:  Imad Uthman; Nadim Kanj; Samir Atweh
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

Review 4.  [Current therapeutic options for giant cell arteritis].

Authors:  E Wipfler-Freissmuth; J Loock; F Moosig; C Dejaco; C Duftner; M Schirmer
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

Review 5.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

Review 6.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Clinical features of polymyalgia rheumatica and giant cell arteritis.

Authors:  Carlo Salvarani; Nicolò Pipitone; Annibale Versari; Gene G Hunder
Journal:  Nat Rev Rheumatol       Date:  2012-07-24       Impact factor: 20.543

Review 8.  Update on the management of giant cell arteritis.

Authors:  Janet Roberts; Alison Clifford
Journal:  Ther Adv Chronic Dis       Date:  2017-03-28       Impact factor: 5.091

9.  Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis.

Authors:  N Kumar Tripathy; S Kumar Chauhan; S Nityanand
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

Review 10.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.